Indications & formulation #
Acute bipolar mania in adults; schizophrenia has a different dose discussion. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Start 2–3 mg/day; increases of 1 mg no sooner than 24 hours if tolerated. Studied adult mania range: 1–6 mg/day.
Contraindications & important cautions #
Hypersensitivity to risperidone/paliperidone is a contraindication. Assess prolactin, movement symptoms, orthostasis and metabolic effects.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Movement symptoms, prolactin effects, orthostasis, sedation and metabolic effects require review.
Interactions #
CYP2D6 and other exposure modifiers matter. Oral and long-acting products are not interchangeable regimens.
Monitoring #
Review movements, prolactin-related symptoms, metabolic status, blood pressure and renal/hepatic context.
Special populations #
Severe renal/hepatic impairment: start 0.5 mg twice daily and titrate slowly. Dementia-related psychosis carries excess mortality risk.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Review relapse risk and reduce under supervision; oral and depot regimens are not interchangeable.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Risperidone
Adult schizophrenia: selected oral label
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 2 mg/day, once or in divided doses.
- Titration
- Increase by 1–2 mg/day at intervals of at least 24 hours; slower titration may be appropriate.
- Treatment range / target
- Label target 4–8 mg/day; individualize to tolerability and response.
- Maximum / limits
- Label studied range extends to 16 mg/day. Doses above 6 mg/day with twice-daily dosing were not more efficacious and caused more EPS; this is not a routine high-dose target.
- Trial & duration
- Use an explicit adequate-dose trial and then reassess.
- Monitoring
- EPS, akathisia, prolactin symptoms, orthostasis and metabolic change.
- Population & organ-function adjustments
- Severe renal/hepatic impairment: start 0.5 mg twice daily; increases above 1.5 mg twice daily at intervals of at least 1 week.
- Important cautions
- Review CYP2D6 inhibitors, carbamazepine and cardiovascular risk; distinguish akathisia from agitation.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Risperidone — Oral tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- Risperidone tablets — product label, sections 2, 5 and 8 · United States · Checked 2026-10-26 · Supports: Risperidone — Adult schizophrenia: selected oral label (Immediate-release tablets)